Weight Watchers Expands Med+ With Access to New Ozempic® pill (semaglutide)
Weight Watchers (NASDAQ: WW) announced it will offer the newly available Ozempic® pill (semaglutide) from Novo Nordisk through its Med+ program, providing members with a once-daily oral GLP-1 treatment option for type 2 diabetes. This addition complements Weight Watchers' holistic support system, including clinical guidance, insurance navigation, a…